Navigation Links
Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

t indicate treatment-limiting toxicity. The most common adverse event in both treatment groups was upper abdominal pain, which occurred in less than 2% of patients.

Prexige has a different chemical structure from other COX-2 inhibitors. It is the only one that does not contain a sulphur molecule, which has been associated with sulphur-related skin reactions in some patients. Prexige also has a short plasma half-life of approximately four hours, yet provides 24-hour pain relief with a once-daily dose.

The clinical trial database for Prexige comprises approximately 40,000 patients, making it one of the largest bodies of evidence for any drug in its class. This includes the results of TARGET (Therapeutic Arthritis Research and Gastrointestinal Trial) involving more than 18,000 patients[10]. Results of this trial showed Prexige also significantly reduced the incidence of upper gastrointestinal complications by 79% in patients not taking aspirin compared to ibuprofen and naproxen[11].

Novartis supports the recommendation of health authorities that anti-inflammatory treatments should be used in appropriate patients at the lowest possible dose for the shortest possible duration.

Disclaimer The foregoing press release contains forward-looking statements such as "can," "may," or similar expressions, or by express or implied discussions regarding potential future regulatory filings or approvals or potential future sales of Prexige® (lumiracoxib). Such forward-looking statements reflect the current views of Novartis regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Prexige® (lumiracoxib) to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Prexige® (lumiracoxib) will be approved for sale in the U.S. or any other additional markets, or for any additional indicatio
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/27/2008)...l, expected by mid-2009 - - Data from second Phas...KVILLE, Md., Aug. 27 /- Hum...nounced it has completed enrollment,and initial do...3,randomized clinical trials of LymphoStat-B(R) (b...rythematosus (SLE). Belimumab is being developed b...
(Date:8/26/2008)... SYNTAX clinical trial, NATICK, Mass., Aug. 26 /P...ion (NYSE: BSX ) today announced the schedule of ... at the European Society of Cardiology,Congress 20...nich, Germany., The Company plans to announce 12-...ercutaneous coronary intervention (PCI) using the ...
(Date:8/26/2008)...afore Pharmaceuticals Inc.,presented data at the S...s,in Cancer in Washington, D.C., announcing the di...that demonstrate significant anticancer,activity i...olecular scaffold has been developed using,computa... kinase inhibitors,as well as isoform-selective sm...
(Date:8/26/2008)...- Healthpoint today announced,that it has initiate...f a,widely prescribed enzymatic debriding agent on... pilot study was prompted, in part, by clinical re...rs and beneficial healing,properties associated wi...he findings from the peer-reviewed literature, as ...
Breaking Medicine Technology:Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 4Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 18915 1Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 18915 2Roches Vidal Honored as 2008 HBA Rising Star 18911 1Roches Vidal Honored as 2008 HBA Rising Star 18911 2American Red Cross of Southeastern Michigan Celebrates Outstanding Volunteers for Years of Service 18906 1American Red Cross of Southeastern Michigan Celebrates Outstanding Volunteers for Years of Service 18906 2International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 5268 1International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 5268 2
...-Apr 16, 2007 - Amgen,(Nasdaq:AMGN) today presente...cebo-controlled Phase 3 study evaluating the,effic...r the,treatment of anemia in patients with active ...("the 103 study"). Aranesp is not,approved for use...ts were presented in an oral session at the 2007 A...
... approach for the treatment,of early and metastati...wswire-FirstCall/ - AEterna,Zentaris Inc. , a glob... endocrine therapy and oncology, today presented a...ormone-releasing,hormone (GHRH) antagonist JMR-132... Cancer Research (AACR) Annual Meeting being held,...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ten, there is a disconnect between what the doctor...sion. Sometimes this gap is so wide//, that crucia...ark because of this gap in grasping the implicatio...searchers feel the use of certain graphics by doct...
...e union cabinet Thursday approved an agreement wit...artered in Seoul for joint vaccine research.// Se...DP), IVI is an international center for research, ...stance for vaccine production in developing countr...
...e accumulation of drug resistance after the failur...ients who had previously experienced only moderate...ts failing treatment at a network of European hosp... that on average, patients who remained on a faili...
...shington - If you are obese, blame it on your gene...s shown that, //if genes called FTO portray mutati...70% chance of being over weight, as compared to pe...gene. Researchers do not have the complete story ...
Other Medicine News:Health News:Graphics- Helps Bridge Gaps in Patients’ Understanding of Medical Condition 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 3
Inquire
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)
Adhesive tape sheets for sealing multiwell plates and blocks;
Microwell Plate Accessories
Medicine Products: